The ladder goes down as well as up
Four dose steps are priced on the homepage, each labelled with the same vial volume and described as a month supply. The two lowest doses cost the same as each other. The next step up costs less than either of them. The top step costs more than all three.
Any assumption that a GLP-1 gets more expensive as the dose rises fails on this seller, in the middle of its own ladder. It is a small thing and it is exactly the kind of thing a price extractor that takes the first or the lowest figure would flatten.
Sold as a brand's compounded version
The product is listed under a name that presents it as the compounded version of a named brand-name drug, and the semaglutide lane is named the same way after a different brand. That is not a comparison drawn in body copy; it is the product name, and it is the address of the product page.
Its FDA warning letter, issued in September 2025, concerns the unlawful sale of unapproved and misbranded drugs online. A compounded preparation is not the approved product whose name it borrows, whatever ingredient the two share.
A legal notice that names no company
The site publishes a block headed as a legal notice, giving a business name, a registered company name, a telephone number and a registered office address. Both names are the trading name, with no corporate form after either. A registered company name with no LLC, Inc. or Corp. behind it is not a legal entity.
A second domain serves the same catalogue, down to the product identifiers and the page structure. One company, two addresses — and a reader landing on the other one has no way to tell it is the same shop.
All American Wellness's published pricing
| Medication | Price | Verified |
|---|---|---|
| Tirzepatide (compounded) | $425per 2 ml vial, which the seller describes as a month supply; no billing period is stated | September 2026source |
| Tirzepatide (compounded) | $425per 2 ml vial described as a month supply; the same figure as the 2.5 mg starting dose | September 2026source |
| Tirzepatide (compounded) | $400⛔ per 2 ml vial described as a month supply, and CHEAPER than both lower doses — the ladder is not monotonic | September 2026source |
| Tirzepatide (compounded) | $450per 2 ml vial described as a month supply; the top of the published ladder | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 198 providers reviewed here are paid partners today; the other 194 are not. See how this works.
See All American Wellness's current price →Good fit if
- Readers who want a complete dose ladder visible before any intake.
- Buyers who prefer a small named clinic with a telephone number to a national platform.
- People checking whether a price really does rise with the dose.
- Anyone who wants the vial volume stated beside the figure.
Look elsewhere if
- Readers who need to know which company they are contracting with.
- Buyers uneasy about a product sold under a brand-name-derived product name.
- Anyone who needs a named compounding pharmacy, a named clinician or a service-area list.
- Readers for whom an FDA warning letter is disqualifying.
How this review was verified
- Re-read the priced homepage and the legal notice on 7 September 2026, comparing requested to effective URLs and running a nonsense path against the host in the same run, which returned a 404.
- Joined text nodes before matching prices; the visible text on this page is a small fraction of its byte size, so a size-based check would describe something other than what a reader sees.
- Read the legal-notice block in full and recorded that neither name carries a corporate form, rather than treating a registered company name as an entity.
- Recorded all four ladder steps, including the one that costs less than the doses below it.
- Screened the brand against FDA's live warning-letter datatable with a positive and a negative control in the same invocation, and re-fetched the letter to confirm its title matches the name, reference number and date; a minted nonsense letter path returned a 404 in the same run.